NEW AP113 Molecular Testing Guidelines for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
9:30–11:30 am
2.0 CME CREDITS
The treatment of adenocarcinoma of the lung has been transformed by the discovery of critical oncogene mutations associated with response to targeted antitumor therapies, most notably EGFR mutation as an indicator of response to erlotinib and ALK rearrangement as an indicator of response to crizotinib. These discoveries have spurred a growing demand for high-quality molecular diagnostic testing of these tumors for patient management and monitoring. This course will present evidence-based professional guidelines for the selection of patients, samples, methodology, and validation strategies that were developed jointly by experts from three organizations: the Association for Molecular Pathology (AMP), the College of American Pathologists (CAP), and the International Association for the Study of Lung Cancer (IASLC).
You will learn to:
- Consult with oncologists, regarding which lung cancer patients should be tested for molecular testing
- Select an appropriate sample for molecular analysis of lung cancers
- Choose an appropriate test menu for molecular testing of lung cancers
- Validate quality molecular tests for lung cancers
Faculty
Marc Ladanyi, MD, FCAP
Neal I. Lindeman, MD, FCAP
Cosponsored by 
and 